As Alnylam Pharmaceuticals approaches its highly anticipated March 23 FDA decision date for a potential expansion of Amvuttra ...

While the continued erosion of Biogen’s multiple sclerosis franchise and weaker-than-expected 2025 guidance doesn’t seem to ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with its substantial $114.5 billion market capitalization, continues to dominate the cystic fibrosis (CF) treatment market while advancing a ...

Royalty Pharma Plc provides drug development services ... Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta ...

Walter Kimble has opened his own Seniors Helping Seniors franchise in Philadelphia with ... childhood vaccines during a 35-year career in the pharmaceutical industry, Walter Kimble has turned ...

AstraZeneca will pay the Barcelona-headquartered pharma company $875 million to buy Eklira, its COPD and asthma treatment, plus a number of other clinical and pre-clinical candidates.

Gujarat Titans are set to experience an ownership shakeup, with Torrent Group acquiring 66 per cent of the franchise.

Despite significant dips in its vaccines sales, the British pharma narrowly beat consensus estimates for Q4 2024 and raised ...